<DOC>
	<DOCNO>NCT02294227</DOCNO>
	<brief_summary>The purpose study provide 16-week efficacy , safety tolerability data versus placebo support use secukinumab 150 mg subcutaneous ( s.c. ) self-administration without load regimen maintenance dose use pre-filled syringe ( PFS ) ass efficacy , safety tolerability 2 year subjects active AS despite current previous NSAID , non-biologic DMARD biologic anti-TNFα therapy</brief_summary>
	<brief_title>16-week Efficacy 2-year Safety , Tolerability Efficacy Secukinumab Participants With Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis Psoriatic Arthritis ( PsA ) classify ClASsification criterion Psoriatic ARthritis ( CASPAR ) criterion . Rheumatoid factor anticyclic citrullinated peptide ( CCP ) antibodies negative . Diagnosis active plaque psoriasis nail change consistent psoriasis . Inadequate control symptom NSAID . Other protocoldefined inclusion criterion apply . Chest Xray chest magnetic resonance imaging ( MRI ) evidence ongoing infectious malignant process . Subjects take high potency opioid analgesic . Previous exposure secukinumab biologic drug directly target interleukin17 ( IL17 ) IL17 receptor . Ongoing use prohibit psoriasis treatment / medication . Subjects ever receive biologic immunomodulating agent except target TNFα . Previous treatment celldepleting therapy . Other protocoldefined exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>AIN457 , psoriatic arthritis , chronic inflammatory disease , load regimen , secukinumab , self-injection</keyword>
</DOC>